| 摘要 |
<p>A process for reducing 2-(11H-dibenzb,eazepin-6-ylmethyl)-1H-isoindole-1,3(2H)-dione to 2-(6,11-dihydro-5H-dibenzb,eazepin-6yl-methyl)-1H-isoindole-1,3(2H)-dione is disclosed, which comprises carrying out the reduction, in an organic solvent, in the presence of a metallic catalyst and of formic acid and/or at least one pharmaceutically acceptable salt thereof; the process is safe and allows to obtain a nearly quantitative conversion without the need of a high pressure.</p> |
